January 13, 2021 08:29 AM ESTUpdated 01:59 PM
Startups

A long­time Pfiz­er chief's ul­tra-qui­et biotech re-emerges with new cash and plans for the clin­ic

Jason Mast

Editor

In Au­gust 2018, a tiny biotech spin­out from Cor­nell an­nounced they had hired for­mer high-rank­ing Pfiz­er ex­ec­u­tive Geno Ger­mano as CEO. And then they …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Lil­ly's board un­der­goes more changes; Mer­ck strat­e­gy chief joins Roger Perl­mut­ter at Eikon

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

Pa­tient dies in Neu­ro­gene's Rett syn­drome study

From vac­cines to psy­che­delics, five drug­mak­ers on what could change un­der a Trump ad­min­is­tra­tion

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times